TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  Benzinga

AstraZeneca's Self-Injectable Lupus Drug Shines In Late-Stage Trial

Benzinga Logo Benzinga By Vandana Singh
AstraZeneca's Self-Injectable Lupus Drug Shines In Late-Stage Trial

AstraZeneca announced positive Phase 3 TULIP-SC trial results for Saphnelo (anifrolumab) subcutaneous injection for lupus treatment. The drug showed statistically significant disease activity reduction (56.2% vs 37.1% placebo) with a favorable safety profile. Saphnelo is already approved in 70+ countries and has treated over 40,000 patients globally.

Insights
JSPRW   negative

The lawsuit alleges the company made false statements about manufacturing controls, potentially misrepresenting product prospects and increasing risks for clinical trials, which suggests significant corporate governance and transparency issues


AZN   positive

Positive Phase 3 trial results for Saphnelo showing statistically significant and clinically meaningful disease activity reduction compared to placebo, with consistent safety profile. Drug already approved in 70+ countries with 40,000+ patients treated. Stock up 0.58% in premarket trading.